Coronado Biosciences, a Burlington, Mass.-based biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, has appointed Harlan F. Weisman, M.D., as its new chairman and CEO.

Wesiman has served as a director for Coronado since August 2012. Prior to that, he was employed by Johnson & Johnson (J&J), where he held a number of leadership positions, and before that he was the head of R&D at Centocor, the developer of Remicade, which was acquired by J&J.

In addition, Glenn L. Cooper, M.D., will step down as executive chairman of the board of the company.